1. Academic Validation
  2. Cycloastragenol inhibits Aβ1-42-induced blood-brain barrier disruption and enhances soluble Aβ efflux in vitro

Cycloastragenol inhibits Aβ1-42-induced blood-brain barrier disruption and enhances soluble Aβ efflux in vitro

  • J Asian Nat Prod Res. 2021 Jun;23(6):556-569. doi: 10.1080/10286020.2020.1786372.
Min-Ye Huang 1 Gu-Ran Yu 1
Affiliations

Affiliation

  • 1 Department of Neurology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
Abstract

This study aimed to evaluate the effect Cycloastragenol (CAG), a triterpenoid saponin isolated from the Radix astragali, on Aβ-induced BBB damage. An immortalized endothelial cell line (bEnd.3) was employed to mimic a BBB. The Western blot, TUNEL staining, Flow cytometric analysis and Enzyme-linked immunosorbent assay were performed. The present results showed that CAG (10, 50, 75 μM) can alleviate oligomer Aβ1-42 induced bEnd.3 cell Apoptosis and increase tight junction scaffold proteins expression. The result also indicated that CAG increased soluble Aβ efflux across BBB via upregulation of the P-gp and downregulation of RAGE expression.[Formula: see text].

Keywords

Alzheimer's disease; amyloid‐β1–42; blood–brain barrier; cycloastragenol.

Figures
Products